Hangzhou Tigermed Consulting Analyst Opinions
- All
- Buy
- Hold
- Sell
Hangzhou Tigermed Consulting Estimates* in CNY
| 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|
| Revenue | 7,057 | 8,996 | 11,111 | 14,114 | 17,104 |
| Dividend | 0.56 | 0.62 | 0.54 | - | - |
| Dividend Yield (in %) | 0.41 % | 0.49 % | 0.37 % | - | - |
| EPS | 3.19 | 3.85 | 4.44 | - | - |
| P/E Ratio | 33.77 | 28.15 | 23.47 | - | - |
| EBIT | 2,759 | 3,394 | 3,919 | 4,491 | 5,441 |
| EBITDA | 2,343 | 2,951 | 3,698 | - | - |
| Net Profit | 2,826 | 3,331 | 3,947 | 3,026 | 3,674 |
| Net Profit Adjusted | 2,187 | 3,039 | 3,607 | 3,026 | 3,674 |
| Pre-Tax Profit | 3,534 | 4,167 | 4,910 | 4,450 | 5,402 |
| Net Profit (Adjusted) | - | - | - | - | - |
| EPS (Non-GAAP) ex. SOE | - | - | - | - | - |
| EPS (GAAP) | 2.85 | 3.48 | 4.13 | - | - |
| Gross Income | 2,986 | 3,928 | 5,240 | 6,270 | 7,640 |
| Cash Flow from Investing | 669 | 344 | 1,159 | - | - |
| Cash Flow from Operations | 2,726 | 2,673 | 3,509 | - | - |
| Cash Flow from Financing | 148 | 206 | 415 | - | - |
| Cash Flow per Share | 3.44 | 2.65 | 3.67 | - | - |
| Free Cash Flow | 1,599 | 2,574 | 3,173 | - | - |
| Free Cash Flow per Share | 1.07 | 1.82 | 2.50 | - | - |
| Book Value per Share | 23.81 | 27.62 | 32.00 | - | - |
| Net Debt | -11,416 | -13,458 | -16,462 | - | - |
| Research & Development Exp. | 287 | 358 | 474 | 621 | 753 |
| Capital Expenditure | 327 | 262 | 325 | - | - |
| Selling, General & Admin. Exp. | 1,130 | 1,464 | 1,844 | - | - |
| Shareholder’s Equity | 21,007 | 23,847 | 28,242 | - | - |
| Total Assets | 26,838 | 31,077 | 37,209 | - | - |
|
Previous Quarter ending 06/30/22 |
Current Quarter ending 09/30/22 |
Next Quarter ending 12/31/22 |
Current Year ending 12/31/22 |
Next Year ending 12/31/23 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 3 | 3 | 3 | 10 | 9 |
| Average Estimate | 0.642 CNY | 0.796 CNY | 0.862 CNY | 3.192 CNY | 3.847 CNY |
| Year Ago | - | 0.600 CNY | - | 3.310 CNY | 3.192 CNY |
| Publish Date | 8/25/2022 | 11/2/2022 | 3/28/2023 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 3 | 2 | 2 | 9 | 9 |
| Average Estimate | 1,305 CNY | 1,909 CNY | 2,019 CNY | 7,057 CNY | 8,996 CNY |
| Year Ago | - | 1,339 CNY | - | 5,214 CNY | 7,057 CNY |
| Publish Date | 8/25/2022 | 11/2/2022 | 3/28/2023 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Hangzhou Tigermed Consulting Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2021 | Hangzhou Tigermed Consulting Co Ltd (A) | 0.48 | 0.38 | CNY |
| 2020 | Hangzhou Tigermed Consulting Co Ltd (A) | 0.32 | 0.20 | CNY |
| 2019 | Hangzhou Tigermed Consulting Co Ltd (A) | 0.25 | 0.39 | CNY |
| 2018 | Hangzhou Tigermed Consulting Co Ltd (A) | 0.30 | 1.04 | CNY |
| 2017 | Hangzhou Tigermed Consulting Co Ltd (A) | 0.26 | 1.11 | CNY |
| 2016 | Hangzhou Tigermed Consulting Co Ltd (A) | - | - | CNY |
| 2015 | Hangzhou Tigermed Consulting Co Ltd (A) | 0.08 | 0.40 | CNY |
| 2014 | Hangzhou Tigermed Consulting Co Ltd (A) | 0.16 | 1.58 | CNY |
| 2013 | Hangzhou Tigermed Consulting Co Ltd (A) | 0.32 | 2.99 | CNY |
| 2012 | Hangzhou Tigermed Consulting Co Ltd (A) | 0.65 | 13.71 | CNY |
| 2011 | Hangzhou Tigermed Consulting Co Ltd (A) | - | - | CNY |
| 2010 | Hangzhou Tigermed Consulting Co Ltd (A) | - | - | CNY |
| 2009 | Hangzhou Tigermed Consulting Co Ltd (A) | - | - | CNY |
*Yield of the Respective Date
Hangzhou Tigermed Consulting Co Ltd (A) Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 0.642 CNY | Q2 2022 Earnings Release | 08/25/2022 |
| Earnings Report | 0.796 CNY | Q3 2022 Earnings Release | 11/02/2022 |
| Earnings Report | 0.862 CNY | Q4 2022 Earnings Release | 03/28/2023 |
| Earnings Report | - | Q1 2023 Earnings Release | 04/26/2023 |
| Earnings Report | - | Q2 2023 Earnings Release | 09/01/2023 |
Hangzhou Tigermed Consulting Profile
Hangzhou Tigermed Consulting Co., Ltd. provides clinical research services for research and development of domestic and foreign pharmaceutical and health related products. Its services include technical services for phase I to phase IV clinical trials, registration and declaration of clinical trials, on-site services, as well as data management and analysis, etc. The company was founded on December 15, 2004 and is headquartered in Hangzhou, China.
Hangzhou Tigermed Consulting Shareholder
| Owner | in % |
|---|---|
| Freefloat | 86.18 |
| Xiao Ping Ye, PhD | 7.83 |
| Zhong Ou Medical Health Hybrid Fund | 6.41 |
| Temasek Holdings Pte Ltd. (Investment Management) | 3.29 |
| China Investment Corp. (Investment Management) | 2.64 |
| Xiao Li Shi | 2.00 |
| Yinhua Prosperity Theme Mixed Fund | 1.80 |
| Yinhua Fund Management Co., Ltd. | 1.63 |
| Allianz Global Investors Fund - China A-Share | 1.44 |
| China Merchants CSI Bio-medicine Index Structured Fund | 1.42 |
| GF Health Care Equity Fund | 1.15 |
| Hangzhou Tigermed Consulting Co., Ltd. | 0.69 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.